Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Foster

Showing results (141-150 of 143) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 143 results.
Eclinicalmedicine|October 16, 2024
High mortality following early initiation of antiretroviral therapy in infants living with HIV from three African countriesAlfredo Tagarro, Sara Domínguez-Rodríguez, Mark Cotton, et al.
JCI Insight|April 1, 2025
Soluble CD13 is a potential mediator of neutrophil-induced thrombogenic inflammation in SARS-CoV-2 infectionPei-Suen Tsou, Ramadan A Ali, Chenyang Lu, et al.
The Lancet. HIV|August 7, 2025
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi processChloe Orkin, Amy Paterson, Alexa Elias, et al.
Pageof 15

Showing results (141-150 of 143) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 143 results.
Eclinicalmedicine|October 16, 2024
High mortality following early initiation of antiretroviral therapy in infants living with HIV from three African countriesAlfredo Tagarro, Sara Domínguez-Rodríguez, Mark Cotton, et al.
JCI Insight|April 1, 2025
Soluble CD13 is a potential mediator of neutrophil-induced thrombogenic inflammation in SARS-CoV-2 infectionPei-Suen Tsou, Ramadan A Ali, Chenyang Lu, et al.
The Lancet. HIV|August 7, 2025
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi processChloe Orkin, Amy Paterson, Alexa Elias, et al.
Pageof 15